IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET.
紐約，2024年6月24日（環球新聞社）-- in8bio，Inc（納斯達克:INAB）是一家領先的臨床階段生物製藥公司，專注於創新的γ-δ T 細胞療法，今天宣佈，首席執行官兼聯合創始人William Ho將在H.C. Wainwrightnd在美國東部時間6月25日下午2:30舉行。將提供現場網絡廣播和重播，在in8bio網站的“新聞與演示文稿”部分下可獲得。
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
https://www.in8bio.com/news-events/events-presentations/2活躍醫藥投資者會議期間加入圓桌討論。了解更多信息請訪問.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogenic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.
關於in8bio
in8bio是一家專注於發現、開發和商業化兩極 Δ T 細胞治療藥物候選品的臨床階段的生物製藥公司。γδT細胞是一種具有獨特性質的T細胞，包括區分健康和疾病組織的能力。IN8bio的DeltEx平台採用同種異體、自體、iPSC和基因修飾方法開發細胞療法，旨在有效識別和清除腫瘤細胞。in8bio已經在美國對INB-400進行了GBM的2期試驗，並進行了兩項涉及固體和血液腫瘤的1期試驗，包括INB-200用於GBM和INB-100用於患有血液惡性腫瘤（包括急性髓系白血病）的半相合骨髓移植患者。in8bio還擁有廣泛的臨床前項目組合，重點是解決其他血液和固體腫瘤癌症。有關更多信息，請訪問in8bio網站。
IN8bio has initiated a Phase 2 trial of INB-400 in GBM in the United States and has two ongoing Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies, including acute myelogenous leukemia, undergoing haplo-matched bone marrow transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers. For more information visit www.IN8bio.com.
in8bio已在美國啓動INB-400的GBM第2期臨床試驗並開展了兩項正在進行的第1期實體和造血瘤臨床試驗，包括INB-200用於GBM和INB-100用於患有血液惡性腫瘤的患者，包括急性髓性白血病，正在進行haplo匹配骨髓移植。in8bio還擁有一個廣泛的臨床前研究項目組合，專注於解決其他血液學和實體腫瘤癌。有關更多信息，請訪問www.IN8bio.com.
Company Contact
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
+1 203.494.7411
gdschulman@IN8bio.com
公司聯繫
Marcia Novero
Innodata Inc.
Mnovero@innodata.com
(201) 371-8015
IN8bio，Inc。
Glenn Schulman，藥劑師，公共衛生碩士
+1 203.494.7411
gdschulman@in8bio.com
Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
投資者
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
Kimberly.ha@kkhadvisors.com
媒體聯繫人
Kimberly Ha
KKH Advisors
917-291-5744
Kimberly.ha@kkhadvisors.com
譯文內容由第三人軟體翻譯。